Complementary and Alternative Therapies in IBD Hype or Hope? Outline: Definition of Complementary and Alternative (CAM) Therapies
|
|
- Evangeline Joseph
- 7 years ago
- Views:
Transcription
1 Complementary and Alternative Therapies in IBD Hype or Hope? Meenakshi Bewtra, MD, MPH, PhD University of Pennsylvania Division of Gastroenterology Center for Clinical Epidemiology & Biostatistics CCEB Outline: Why CAM? Alternative therapies in IBD Acupuncture and moxibustion Aloe Vera Andrographis panniculata extract Wormwood Curcumin Trichuris suis Cannabis Fish oil Conclusion Definition of Complementary and Alternative (CAM) Therapies a group of diverse medical and health care systems, practices and products that are not presently considered part of conventional medicine. National Center for Complimentary and Alternative Medicine (NCCAM) Complementary and Alternative are Different Complementary: using non-mainstream approach together with conventional medicine Alternative: using non-mainstream approach in place of conventional medicine
2 Use of CAM in N. America and Europe Current use: 11-34% Current and past use: 21-60% Hilsden et al, IBD 2011:17, Most common CAM therapies used in IBD Hilsden et al, IBD 2011:17, Issues in evaluating CAM in IBD Lack of high-quality studies Lack of studies in IBD population Studies assessing CAM often suffer from inferior quality small sample sizes lack of adequate controls inadequate study designs weak results even when positive poor reporting of results no real follow-up studies
3 Why do IBD patients pursue CAM? Existing therapies are not working Fear of side effects of current available therapies they make sense Desire for greater control over their life and their IBD Value of treating the whole person Internet hype and misinformation Improvement in concomitant IBS Because we have not cured IBD yet! Outline: Why CAM? Alternative therapies in IBD Acupuncture and moxibustion Aloe Vera Andrographis panniculata extract Wormwood Curcumin Trichuris suis Cannabis Fish oil Conclusion Alternative Therapies in IBD (for today) Acupuncture and moxibustion Aloe Vera Andrographis panniculata extract Wormwood Curcumin Trichuris suis Cannabis Fish oil
4 Acupuncture and Moxibustion: UC Single-center single blind randomized controlled trial 29 UC patients mild-mod disease (CAI 4-10) stable meds for 4 weeks 15 patients 10 Acu/Mox sessions over 5 weeks 14 patients 10 Sham sessions over 5 weeks Small differences in outcome (moxa/acupuncture vs sham acupuncture) CAI: vs (p=0.048) Both groups improved general well-being and quality of life (no difference between groups) Both traditional and sham offer benefit Joos et al Scand J of Gastro 2006; 41: Acupuncture and Moxibustion: CD Single-center single blind randomized controlled trial 51 CD patients mild-mod disease (CDAI ) stable meds for 4 weeks (no AZA/6-MP/MTX) 27 patients 10 Acu/Mox sessions over 4 weeks 24 patients 10 Sham sessions over 4 weeks Both groups improved general well-being and quality of life Moxa/acupuncture group improved CDAI more CDAI: vs (p=0.003) Both traditional and sham offer benefit, but moxa/acupuncture more Joos et al Digestion 2004, 69(3): Aloe Vera Gel: UC Single-center single blind randomized controlled trial 44 UC patients mild-mod disease (SCCAI 4-10) stable meds for 4 weeks 30 patients 100 ml Aloe Vera Gel BID for 4 weeks 14 patients 100 ml Placebo BID for 4 weeks Clinical response: 47% vs 14% (p<0.05) Clinical remission: 30% vs 7% (p=0.09) Sigmoidoscopy scores no different Histological scores improved with aloe vera but not placebo (p=0.03) Conclusion: mixed results but promising. Needs more study Langmead et al Al Pharm Ther 2004; 19:
5 CDAI Andrographis panniculata extract Study: Sandborn, 5 countries USA/Europe, 2013 Population: Active UC Patients: 224 CAM: 1800 mg daily Comparator: placebo Duration: 8 weeks Remission/Response: 38% (CAM) vs 25% (PBO), p=0.1 60% (CAM) vs 40% (PBO), p=0.02 Phase III clinical trial currently enrolling patients with UC on mesalamine Wormwood: CD Multi-centre double blind randomized placebo controlled trial 40 CD patients CDAI > 170 Excluded IFX-treated patients 20 patients Wormwood capsules 500mg TID 20 patients Wormwood capsules 500mg TID Omer et al Phytomedicine 2007; 14: Wormwood: CD Multi-centre double blind randomized placebo controlled trial 400 Placebo Wormwood (n=20) 300 (n=20) P=0.01 * * proportion with 70 pt dec. in CDAI Week Baseline Double blind treatment Follow up observation period Omer et al Phytomedicine 2007; 14: 87-95
6 Patients in Remission (%) Curcumin Multi-center double blind randomized maintenance trial in quiescent UC 89 UC patients CAI 4 No steroids/aza/6mp/csa patients relapsed 2 patients relapsed Treatment Period X 2 = patients Curcumin 1g po BID + 5-ASA 44patients Placebo 1g po BID + 5-ASA 8 patients relapsed Curcumin 8 patients relapsed Follow up Period NS Placebo 3 months 6 months 9 months 12 months Hanai et al Clin Gastro Hep 2006; 4: Curcumin Multi-center double blind randomized controlled trial in active UC 50 UC patients CAI 5-12 Stable AZA/6MP; no IFX, steroids 26 patients Curcumin 3g po qd + 5-ASA 24 patients Placebo 3g po qd + 5-ASA Lang et al Clin Gastro Hep 2015; Aug;13(8): Parasites: The question or the answer? The Environmental Illness Resource webpage (accessed 8/2015)
7 Trichuris suis ova (worm eggs) Safety and Tolerability of Trichuris ova in CD 1 Study: 36 patients (2 to 6 mo F/U) Results: GI symptoms: 7( 25.9%) in ova vs 3 (33.3%) in placebo group. No dose dependent relationship. No clinically meaningful changes in GI signs and symptoms. Trichuris suis therapy for active UC 2 Study: RCT of 54 pts (12 wk Tx) Results: Clinical Outcomes Clinical response ( UCDAI 4) TSO (n=30) 43% (13/30) Placebo (n=24) 16.7% (4/24) Cochrane: Insufficient evidence regarding efficacy and safety of helminth therapy further RCT needed 3 1. Sandborn W et al. Aliment Pharmacol Ther. 2013;38(3): ; 2. Summers RW et al. Gastroenterology 2005;128(4)825-32; 3. Gark SK et al Cochrane 2014 Trichuris suis ova (worm eggs) Schölmerich J, et al., (2014), Efficacy and safety of Trichuris suis ova for treatment of mildly-to-moderately active Crohn's disease: A randomized, double-blind, placebo-controlled, phase II study, UEG Journal, 2(1S):A123 (OP392) Phase II clinical trial of 252 CD pts treated with T. suis eggs Study did not meet its primary endpoint of improving response nor the key secondary endpoint of remission Ongoing study: Phase II RCT of Suis Ova Treatment in left-sided UC and its effects on Mucosal Immune State and Microbiota (NCT ) Treatment arms: 7500 Trichuris suis ova every 2 weeks for 10 weeks versus placebo P-value 0.04 Cannabis and IBD: patients perspective 18% of patients of surveyed patients reported current or past use Heard cannabis would help 46% Frustrated with their disease 41% Wanted to try a different approach 38% Medications prescribed haven t worked 27% 39% of patients discussed cannabis use with their physicians 82% of patients reported physicians were indifferent or not supportive of cannabis use for IBD treatment 82% plan to continue using cannabis for as part of their IBD treatment 88% would recommend cannabis to other IBD patients Storr et al. Inflamm Bowel Dis 2014;20:
8 Cannabis and IBD: patients perspective 91% of cannabis users indicated it helped with their IBD symptoms diarrhea joint pain 29% 48% abdominal cramps abdominal pain Cannabis users: More severe disease activity More abdominal pain More hospitalizations for IBD More flares within the past year 77% 84% 0% 20% 40% 60% 80% 100% More surgeries for IBD More analgesic use, including narcotics More complementary and alternative medicine use Storr et al. Inflamm Bowel Dis 2014;20: Mechanism of Cannabinoid Derivatives in IBD Unknown Appetite stimulant Bowel relaxant/anticholinergic No evidence that it is anti-inflammatory Very little clinical evidence demonstrating efficacy Controlled Trial of THC in CD Inclusion: IBD patients with CDAI>200 refractory to steroids, IMMs or anti-tnfs. RCT of Δ9-tetrahydrocannabinol (THC) Cigarettes with 115mg THC vs no THC Primary endpoint complete remission Clinical Outcomes Clinical remission Clinical response (CDAI >100) THC (n=11) Placebo (n=10) P-value 45% (5/11) 10% (1/10) % (10/11) 40% (4/10) Naftali T et al. Clin Gastroenterol Hepatol 2013;11:
9 Controlled Trial of THC in CD: Objective data Naftali T et al. Clin Gastroenterol Hepatol 2013;11: Controlled Trial of THC in CD: Objective data No endoscopic data / objective evidence of improvement in inflammation No difference in objective parameters of disease activity No difference in CRP change 3 cannabis patients had a decrease in CRP > 0.5mg/dL 2 placebo patients had a decrease in CRP > 0.5mg/dL 19/21 patients were able to tell which group they were in Essentially not blinded More studies needed if convincing data desired! Naftali T et al. Clin Gastroenterol Hepatol 2013;11: Fish oil in CD Two multinational multi-center randomized doubleblind placebo-controlled studies (EPIC-1, EPIC-2) Patients with CD (CDAI <150) assigned 4g/d FFA or PBO for 58 weeks Feagan B et al 2008 JAMA
10 Outline: Why CAM? Alternative therapies in IBD Acupuncture and moxibustion Aloe Vera Andrographis panniculata extract Wormwood Curcumin Trichuris suis Cannabis Fish oil Conclusion Conclusion: summary of IBD CAM therapies (from today) Compound Moxibustion/Acup Aloe Vera Andrographis panniculata Wormwood Curcumin Trichuris suis Cannabis Fish oil Conclusion Small superiority in UC activity index Superior in CD activity index Superior in UC activity index but no endoscopic change Promising, RCT ongoing, perhaps first herbal backed by real clinical trial data No clear statistical comparisons, looked promising (but would you trust CAM from study with no stats) Improvement at 6 months for UC maintenance Superior for UC induction for those failing 2 weeks 5ASA, reasonable data Neg CD study, Study ongoing in UC Improves symptoms, not inflammation Not effective in maintaining remission in Crohn s Conclusion: how to integrate CAM First, do no harm: Ensure no opportunity cost (ie, do not delay treating a serious illness for which there is known effective therapy); If the CAM therapy carries little risk of harm, then consider its use and follow the patient closely; If the CAM therapy carries serious risk of harm, advise the patient accordingly and follow the patient closely; Where possible, it is recommended to try to follow an evidence-based rationale for therapy Where the evidence is lacking, try to maintain an open mind and a balanced approach. Consider the patient s reason for pursuing CAM
11 Why do IBD patients pursue CAM? Existing therapies are not working Fear of side effects of current available therapies Internet hype and misinformation Improvement in concomitant IBS Desire for greater control over their life and their IBD Value of treating the whole person Because we have not cured IBD yet! Optimize therapy; refer if necessary Appropriate education about therapies and risks You re doing it now! If little harm, and improving IBS, consider continuing CAM therapy Improve shared-decision making Refer to resources Ask about quality of life and depression; consider appropriate referrals Crohn s and Colitis Foundation of America Thank you
Evidence of Crohn s Disease. Case Presentation
Witt Wait to Treat tutiled Until Endoscopic Evidence of Crohn s Disease Raymond Cross, MD, MS, AGAF Associate Professor of Medicine Director, IBD Program University of Maryland School of Medicine Co-Director,
More information2. FRAGESTELLUNGEN DER VORGESTELLTEN ARBEITEN 26. 3.1 Wirksamkeit der Akupunktur bei ausgewählten Schmerzerkrankungen
2. FRAGESTELLUNGEN DER VORGESTELLTEN ARBEITEN 26 3 RELEVANTE ORIGINALARBEITEN 3.1 Wirksamkeit der Akupunktur bei ausgewählten Schmerzerkrankungen Brinkhaus B, Becker-Witt C, Jena S, Linde K, Streng A,
More informationWhat are the Unmet Needs in the Management of IBD?
23/6/214 What are the Unmet Needs in the Management of IBD? Shane Devlin, MD, FRCPC Inflammatory Bowel Disease Group The University of Calgary Some Real Cases: #1 32 yo male with pan UC. Grumbling phenotype
More informationTop Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms. Stephen B. Hanauer, M.D. University of Chicago
Top Down vs. Step Up Therapy Biologics in IBD: Treatment Algorithms Stephen B. Hanauer, M.D. University of Chicago Treatment Goals c.2008 Induce and maintain response/remission Prevent complications Disease
More information11/10/2014. New Treatments in IBD: When, Whom and How. Background. Background. Options. Disease Assessment. What is the evidence?
New Treatments in IBD: When, Whom and How. Background Options Disease Assessment What is the evidence? Kofi Clarke MD, FACP,FRCP (Lond) Clinical Associate Professor, Chief, Gastroenterology, Hepatology
More informationDrugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author
Version History Policy Title Drugs for MS.Drug fact box cannabis extract (Sativex) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further
More informationBriefing Document. Food and Drug Administration. Center for Drug Evaluation and Research
Briefing Document Food and Drug Administration Center for Drug Evaluation and Research Meeting: Joint Meeting of the Gastrointestinal Drugs Advisory Committee (GIDAC) and the Drug Safety and Risk Management
More informationTREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER
Press information for journalists only TREATING INFLAMMATORY BOWEL DISEASE (IBD) BACKGROUNDER Why treat IBD? IBD describes a range of chronic diseases of the gastrointestinal system, encompassing Ulcerative
More informationEVIDENCE BASED TREATMENT OF CROHN S DISEASE. Dr E Ndabaneze
EVIDENCE BASED TREATMENT OF CROHN S DISEASE Dr E Ndabaneze PLAN 1. Case presentation 2. Topic on Evidence based Treatment of Crohn s disease - Introduction pathology aetiology - Treatment - concept of
More informationOriginal Policy Date
MP 5.01.20 Tysabri (natalizumab) Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local Policy/12:2013 Return to Medical Policy Index Disclaimer
More informationProbiotics for the Treatment of Adult Gastrointestinal Disorders
Probiotics for the Treatment of Adult Gastrointestinal Disorders Darren M. Brenner, M.D. Division of Gastroenterology Northwestern University, Feinberg School of Medicine Chicago, Illinois What are Probiotics?
More informationPROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain
P a g e 1 PROTOCOL SYNOPSIS Evaluation of long-term opioid efficacy for chronic pain Clinical Phase 4 Study Centers Study Period 25 U.S. sites identified and reviewed by the Steering Committee and Contract
More informationClostridium Difficile Colitis. Presented by Mark Skains August 2003
Clostridium Difficile Colitis Presented by Mark Skains August 2003 What is Clostridium Difficile Gram positive rod Produces spores (hang out in diverticula) Forms Endotoxin A + B which cause diarrhea.
More informationNasdaqGS: SNTS. September 5, 2012
NasdaqGS: SNTS September 5, 2012 Safe Harbor This presentation may include forward-looking statements that are based on management s beliefs and assumptions and on information currently available to management.
More informationTelemedinsk udvikling
F A C UL T Y O F HE AL T H A ND ME D I C A L S C I E N C E S U N I V E R S I T Y O F C O P E N H A G E N Telemedinsk udvikling Motivational Interviewing Sygeplejerskens rolle - i centrum af ehealth Fagligt
More informationWeek 12 study results
Week 12 study results 15 April 2015 Copyright 2015 Galapagos NV Disclaimer This document may contain certain statements, including forward-looking statements, such as statements concerning the safety and
More informationCrohn s Disease. From research to bedside
Crohn s Disease From research to bedside Primary Care Of The Crohn s Disease Patient Primary Physician s Concerns Vaccination Cancer Cervical Skin Osteoporosis Problems Associated With Vaccinating The
More informationChoosing Outcome Measures in Pediatric IBD. Anne M Griffiths, MD Hospital for Sick Children University of Toronto Toronto, Canada
Choosing Outcome Measures in Pediatric IBD Anne M Griffiths, MD Hospital for Sick Children University of Toronto Toronto, Canada Disclosures The content of this presentation reflect my personal opinions
More informationDecision systems in quality registries
Decision systems in quality registries Stockholm Dec 9 th, 2014 Jonas Halfvarson, MD, PhD Dept of Gastronterology, Faculty of Medicine and Health, Örebro University 1 Quality registries for chronic diseases
More informationVersion History. Previous Versions. Policy Title. Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box Glatiramer Acetate Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields
More informationPresented by: Jean Yoo-Campbell, Matthew Konerman, Monica Konerman, Jean Yoo Campbell, Christian Gocke, Eunpi Cho Donald Lynch
Bass N.M., et. al. N Engl J Med 2010; 362:1071-1081 Presented by: Jean Yoo-Campbell, Matthew Konerman, Monica Konerman, Jean Yoo Campbell, Christian Gocke, Eunpi Cho Donald Lynch Faculty Advisor: Dr. Fred
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More informationConsider the following from a recent study published in the British Journal of Medicine(3):
September 10, 2015 Ellie Garrett Health Services Policy Analyst Minnesota Department of Human Services Re: Expanding acupuncture s role My name is Matthew Bauer, L.Ac. and I am President of the Non-Profit
More informationVersion History. Previous Versions. Drugs for MS.Drug facts box fingolimod Version 1.0 Author
Version History Policy Title Drugs for MS.Drug facts box fingolimod Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review Date Supersedes/New (Further fields as required
More informationLaquinimod Polman, C. et al. Neurology 2005;64:987-991
Laquinimod Polman, C. et al. Neurology 2005;64:987-991 Multicenter, double-blind, randomized trial, patients with RR MS received 0.1 mg or 0.3 mg laquinimod or placebo as three daily tablets for 24 weeks
More informationProduct: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac
PUBLIC SUMMARY DOCUMENT Product: Tazarotene, cream, 500 micrograms per g (0.05%) and 1.0 mg per g (0.1%), 30 g, Zorac Sponsor: Genepharm Australasia Ltd Date of PBAC Consideration: July 2007 1. Purpose
More informationStudy Design. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D. Ellis Unger, M.D. Ghanshyam Gupta, Ph.D. Chief, Therapeutics Evaluation Branch
BLA: STN 103471 Betaseron (Interferon β-1b) for the treatment of secondary progressive multiple sclerosis. Submission dated June 29, 1998. Chiron Corp. Date: March 11, 2003 Reviewer: Jawahar Tiwari, Ph.D.
More informationCirrhosis and HCV. Jonathan Israel M.D.
Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment
More informationOpportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD
Opportunistic Infections Related to Immune Suppressant and Biologic Drug Therapy in IBD Raymond Cross, M.D., M.S., AGAF Associate Professor of Medicine Director of the Inflammatory Bowel Disease Program
More information33 % of whiplash patients develop. headaches originating from the upper. cervical spine
33 % of whiplash patients develop headaches originating from the upper cervical spine - Dr Nikolai Bogduk Spine, 1995 1 Physical Treatments for Headache: A Structured Review Headache: The Journal of Head
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 19 March 2003 CPMP/EWP/785/97 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) POINTS TO CONSIDER
More informationVersion History. Previous Versions. for secondary progressive MS (SPMS) Policy Title. Drugs for MS.Drug facts box Interferon beta 1b
Version History Policy Title Drugs for MS.Drug facts box Interferon beta 1b for secondary progressive MS (SPMS) Version 1.0 Author West Midlands Commissioning Support Unit Publication Date Jan 2013 Review
More informationPRESENTATION. Probiotics in the Treatment of Human Inflammatory Bowel Diseases. Update 2011
PRESENTATION Probiotics in the Treatment of Human Inflammatory Bowel Diseases Update 2011 Bartolomeus Joannes Meijer, MSc and Levinus Albert Dieleman, MD, PhD Abstract: Crohn s disease, ulcerative colitis,
More informationPatient Input Information Clinical Trials Outcomes Common Drug Review
CDEC FINAL RECOMMENDATION USTEKINUMAB (Stelara Janssen Inc.) Indication: Psoriatic Arthritis Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that ustekinumab not be listed at the submitted
More informationMIND-BODY THERAPIES FOR HYPERTENSION
MIND-BODY THERAPIES FOR HYPERTENSION Systematic Review and Meta-Analysis Ather Ali, ND, MPH (1), David L. Katz, MD, MPH (1,2), Michael B. Bracken, PhD, MPH (2). (1)Yale-Griffin Prevention Research Center
More informationTerapia con farmaci biologici e non nella. Sandro Ardizzone. Azienda Ospedaliera Fatebenefratelli e. Ospedale di Rilievo Nazionale Milan
Terapia con farmaci biologici e non nella Colite Ulcerosa Severa/Refrattaria Sandro Ardizzone Gastrointestinal Unit Azienda Ospedaliera Fatebenefratelli e Oftalmico Ospedale di Rilievo Nazionale Milan
More informationComparison/Control Groups. Mary Foulkes, PhD Johns Hopkins University
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationOptimizing Treatment Strategies in the Management of Inflammatory Bowel Disease ( IBD )
Inflammatory Bowel Disease Center Optimizing Treatment Strategies in the Management of Inflammatory Bowel Disease ( IBD ) Russell D. Cohen, M.D. F.A.C.G. A.G.A.F. Professor of Medicine, Pritzker Medical
More informationMedication Management of Depressive Disorders in Children and Adolescents. Satya Tata, M.D. Kansas University Medical Center
Medication Management of Depressive Disorders in Children and Adolescents Satya Tata, M.D. Kansas University Medical Center First Line Medications SSRIs Prozac (Fluoxetine): 5-605 mg Zoloft (Sertraline):
More informationMeasuring severity of disease and defining treatment benefit using the Simple Endoscopic Activity Score (SES-CD)
Measuring severity of disease and defining treatment benefit using the Simple Endoscopic Activity Score (SES-CD) Jean-Frederic COLOMBEL Icahn Medical School at Mount Sinai, New York J-F Colombel has served
More informationFREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C
FREEDOM C: A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C SR in Combination with an ERA and/or a PDE-5 Inhibitor
More informationCrohn s and Colitis Center
Crohn s and Colitis Center Dedicated to caring for patients with inflammatory bowel disease Crohn s disease and ulcerative colitis. The Crohn s and Colitis Center is the only center in New England exclusively
More informationEndoscopy is an important diagnostic and therapeutic
ORIGINAL ARTICLE Appropriateness and Diagnostic Yield of Colonoscopy in the Management of Patients with Ulcerative Colitis: A Prospective Study in an Open Access Endoscopy Service Gianpiero Manes, MD,
More informationA Phase 2 Study of Interferon Beta-1a (Avonex ) in Ulcerative Colitis
A Phase 2 Study of (Avonex ) in Ulcerative Colitis - Study Results - ClinicalTrials.gov A Phase 2 Study of (Avonex ) in Ulcerative Colitis This study has been completed. Sponsor: Biogen Idec Information
More informationThe submission positioned dimethyl fumarate as a first-line treatment option.
Product: Dimethyl Fumarate, capsules, 120 mg and 240 mg, Tecfidera Sponsor: Biogen Idec Australia Pty Ltd Date of PBAC Consideration: July 2013 1. Purpose of Application The major submission sought an
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationDeveloping Innovative Therapeutics for People with Orphan Liver Disease
Developing Innovative Therapeutics for People with Orphan Liver Disease PIPELINE PROGRESS AND FIRST QUARTER 2015 EARNINGS UPDATE NASDAQ: OCRX Forward-Looking Statements Certain statements in this presentation
More informationMillions of Americans suffer from abdominal pain, bloating, constipation and diarrhea. Now new treatments can relieve your pain and discomfort.
3888-IBS Consumer Bro 5/8/03 10:38 AM Page 1 TAKE THE IBS TEST Do you have recurrent abdominal pain or discomfort? YES NO UNDERSTANDING IRRITABLE BOWEL SYNDROME A Consumer Education Brochure Do you often
More informationCrohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals. Sponsored Research Program in Inflammatory Bowel Disease
Crohn s and Colitis Foundation of Canada / Vertex Pharmaceuticals Sponsored Research Program in Inflammatory Bowel Disease Presentation Overview Background on inflammatory bowel disease Partner Overview
More informationEffective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm
Effective for dates of service on or after January 1, 2015 refer to: https://www.bcbsal.org/providers/drugpolicies/index.cfm Name of Policy: Tysabri (natalizumab) Policy #: 281 Latest Review Date: October
More informationSponsor Novartis Pharmaceuticals
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study
More informationJAN 1 6 2007 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED
E DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 - JAN 1 6 2007 WARNING LETTER CERTIFIED MAIL RETURN RECEIPT REQUESTED Lawrence S. Kim, M.D.
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationSummary 1. Comparative-effectiveness
Cost-effectiveness of Delta-9-tetrahydrocannabinol/cannabidiol (Sativex ) as add-on treatment, for symptom improvement in patients with moderate to severe spasticity due to MS who have not responded adequately
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationWhat is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
What is the Optimal Front-Line Treatment for mrcc? Michael B. Atkins, MD Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center The Case for Immunotherapy in mrcc 1. Achieves patient s goal 2.
More informationThe Oxford IBD Service
Gastroenterology Unit, John Radcliffe Hospital The Oxford IBD Service Information for patients Information for patients 1 The Oxford Inflammatory Bowel Disease (IBD) Service Consultant Gastroenterologists
More informationPragmatic Seamless Design for Efficacy Trial of Asthma Management with reduced Cost. Mei Lu, PhD Christine Joseph, Ph.D
Pragmatic Seamless Design for Efficacy Trial of Asthma Management with reduced Cost Mei Lu, PhD Christine Joseph, Ph.D Henry Ford Health System May 19, 2013 Puff City Pragmatic RCT: Partners HFHS Clinical
More informationDisclosures. Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta, Atlanta, GA Disclosures Consultant and Speaker for Biogen Idec, TEVA Neuroscience, EMD Serrono, Mallinckrodt, Novartis, Genzyme, Accorda Therapeutics
More informationSummary of the risk management plan (RMP) for Cerdelga (eliglustat)
EMA/743948/2014 Summary of the risk management plan (RMP) for Cerdelga (eliglustat) This is a summary of the risk management plan (RMP) for Cerdelga, which details the measures to be taken in order to
More informationto Part of Dossier: Name of Active Ingredient: Title of Study: Quality of life study with adalimumab in rheumatoid arthritis. ESCALAR.
2.0 Synopsis Abbott Laboratories Name of Study Drug: Individual Study Table Referring to Part of Dossier: Adalimumab (HUMIRA) (For National Authority Use Only) Name of Active Ingredient: Adalimumab Title
More informationMeasure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care
Measure #257 (NQF 1519): Statin Therapy at Discharge after Lower Extremity Bypass (LEB) National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More information2.0 Synopsis. Vicodin CR (ABT-712) M05-765 Clinical Study Report R&D/07/095. (For National Authority Use Only) to Part of Dossier: Volume:
2.0 Synopsis Abbott Laboratories Name of Study Drug: Vicodin CR Name of Active Ingredient: Hydrocodone/Acetaminophen Extended Release (ABT-712) Individual Study Table Referring to Part of Dossier: Volume:
More informationFORM 6-K. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549. Report of Foreign Private Issuer
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 For the month of August 2011
More informationChoosing a placebo EAPC Research Forum Trondheim 2008
Choosing a placebo EAPC Research Forum Trondheim 2008 Claudia Bausewein Department of Palliative Care, Policy & Rehabilitation King s College London History Religious context Psalm 116: Placebo Domine
More informationCorporate Presentation May 13, 2015
Corporate Presentation May 13, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events and
More informationRobot-Assisted Stroke Rehabilitation
American Heart Association International Stroke Conference, 2012, New Orleans Robot-Assisted Stroke Rehabilitation Albert Lo, M.D., PhD Departments of Neurology and Epidemiology Associate Director, Center
More informationIssues Regarding Use of Placebo in MS Drug Trials. Peter Scott Chin, MD Novartis Pharmaceuticals Corporation
Issues Regarding Use of Placebo in MS Drug Trials Peter Scott Chin, MD Novartis Pharmaceuticals Corporation Context of the Guidance The draft EMA Guidance mentions placebo as a comparator for superiority
More informationMARIJUANA : A DRUG, MEDICINE, OR A DRUG AS MEDICINE? Robert Roose, MD, MPH, FASAM Sisters of Providence Health System Jan 15, 2016
MARIJUANA : A DRUG, MEDICINE, OR A DRUG AS MEDICINE? Robert Roose, MD, MPH, FASAM Sisters of Providence Health System Jan 15, 2016 EDUCATIONAL OBJECTIVES Describe the mechanism of action and effects of
More informationResearch in IBD at University of Colorado Denver
Research in IBD at University of Colorado Denver Blair Fennimore, MD Assistant Professor of Medicine Division of Gastroenterology and Hepatology UCH Crohn s and Colitis Center Mucosal Inflammation Program
More informationPrior Authorization, Pharmacy and Health Case Management Information. Prior Authorization. Pharmacy Information. Health Case Management
Prior Authorization, Pharmacy and Health Case Management Information The purpose of this information sheet is to provide you with details on how Great-West Life will be assessing and managing your claim
More informationApixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial
Apixaban Plus Mono vs. Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights from the APPRAISE-2 Trial Connie N. Hess, MD, MHS, Stefan James, MD, PhD, Renato D. Lopes, MD, PhD, Daniel M. Wojdyla,
More informationUPDATED INVESTOR PRESENTATION June 2015
UPDATED INVESTOR PRESENTATION June 2015 Forward-looking Statements All statements in this presentation other than those of historical fact, including statements regarding our clinical development plans
More informationIntegrative Therapies and Preconception Health. Debbie Ringdahl DNP, RN, CNM
Integrative Therapies and Preconception Health Debbie Ringdahl DNP, RN, CNM Definitions Preconception Health primary care? CAM complementary (together with) and alternative medicine (in place of) Integrative
More informationRiociguat Clinical Trial Program
Riociguat Clinical Trial Program Riociguat (BAY 63-2521) is an oral agent being investigated as a new approach to treat chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension
More informationA Multi-Centre Efficacy Trial of Naltrexone Maintenance Therapy in Hong Kong
A Multi-Centre Efficacy Trial of Naltrexone Maintenance Therapy in Hong Kong Executive Summary 1. Study Background 1.1 In May 1999, upon the recommendations of the Action Committee Against Narcotics (ACAN)
More informationEarly Colonoscopy in Patients with Acute Diverticulitis Simon Bar-Meir, M.D.
Early Colonoscopy in Patients with Acute Diverticulitis Simon Bar-Meir, M.D. Professor of Medicine Germanis Kaufman Chair of Gastroenterology Director, Dept. of Gastroenterology Chaim Sheba Medical Center,
More informationAcupuncture and moxibustion in the treatment of ulcerative colitis: A randomized controlled study
Scandinavian Journal of Gastroenterology, 2006; 41: 1056 1063 ORIGINAL ARTICLE Acupuncture and moxibustion in the treatment of ulcerative colitis: A randomized controlled study STEFANIE JOOS 1,2, NICOLE
More informationUlcerative Colitis & Proctitis. About Ulcerative Colitis & Proctitis
Ulcerative Colitis & Proctitis About Ulcerative Colitis & Proctitis When you first learn that you have ulcerative colitis, you will probably feel overwhelmed. You may not even have heard of ulcerative
More informationOral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial
Oral Zinc Supplementation as an Adjunct Therapy in the Management of Hepatic Encephalopathy: A Randomized Controlled Trial Marcus R. Pereira A. Study Purpose Hepatic encephalopathy is a common complication
More informationRheumatoid Arthritis www.arthritis.org.nz
Rheumatoid Arthritis www.arthritis.org.nz Did you know? RA is the second most common form of arthritis Approximately 40,000 New Zealanders have RA RA can occur at any age, but most often appears between
More informationImmunex Corporation Novantrone (Mitoxantrone HCL) P&CNS Advisory Committee Briefing Document. Page 020
Page 020 4.0 Efficacy of Mitoxantrone in Multiple Sclerosis The efficacy of mitoxantrone in MS was demonstrated in two well-designed, randomized trials: Studies 901 and 902. The study design and efficacy
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationAcute & Chronic Pain Management (requiring opioid analgesics) in Patients Receiving Pharmacotherapy for Opioid Addiction
Acute & Chronic Pain Management (requiring opioid analgesics) in Patients Receiving Pharmacotherapy for Opioid Addiction June 9, 2011 Tufts Health Care Institute Program on Opioid Risk Management Daniel
More informationWellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015
Wellness for People with MS: What do we know about Diet, Exercise and Mood And what do we still need to learn? March 2015 Introduction Wellness and the strategies needed to achieve it is a high priority
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Tysabri
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF I. Requirements for Prior Authorization of Tysabri A. Prescriptions That Require Prior Authorization All prescriptions for Tysabri must be prior authorized.
More informationHow To Write A Systematic Review
Formulating the Review Question & Writing a Protocol Madhukar Pai, MD, PhD Associate Professor Department of Epidemiology & Biostatistics McGill University, Montreal, Canada Email: madhukar.pai@mcgill.ca
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationTestimony of Sidney Wolfe M.D. Health Research Group of Public Citizen FDA Drug Safety and Risk Management Advisory Committee
Testimony of Sidney Wolfe M.D. Health Research Group of Public Citizen FDA Drug Safety and Risk Management Advisory Committee Adequacy of Lotronex (alosetron) REMS July 10, 2013 (I have no financial conflict
More informationIn the last decade, there have been major changes in the
233 Promising New Treatments for Rheumatoid Arthritis The Kinase Inhibitors Yusuf Yazici, M.D., and Alexandra L. Regens, B.A. Abstract Three major advances over the last decade have impacted the way we
More informationMedical Research from Medical Records Mikel Aickin, PhD Family & Community Medicine University of Arizona, USA The Problem Medical researchers believe that therapeutic knowledge comes from randomized clinical
More informationHow To Treat Chronic Pain With Nonpharmacological Medicine
. Report to The Vermont Legislature Treatment of Chronic Pain In Accordance with Act 75, Sections 14(d)(2) and 14a An Act Relating to Strengthening Vermont s Response to Opioid Addiction and Methamphetamine
More informationWorms for Your Health --
Worms for Your Health -- In this Dr. s Q&A, Joel Weinstock, M.D., explains why he tells his patients to drink a glass full of worm eggs. Tell me a little about inflammatory bowel disease. Dr. Weinstock:
More informationBach Flower Remedies for pain relief and psychological problems
Bach Flower Remedies for pain relief and psychological problems Systematic Review Decision Support Document Nr. 17 ISSN online 1998-0469 Bach Flower Remedies for pain relief and psychological problems
More informationSativex. Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353
Sativex Spirella Building, Letchworth, SG6 4ET 01462 476700 www.mstrust.org.uk reg charity no. 1088353 Sativex Date of issue: July 2010 Review date: July 2011 Contents 1. Introduction 1 2. What is Sativex?
More informationCytori Therapeutics NASDAQ: CYTX
Cytori Therapeutics Scleroderma Informational Session January 2015 Restoring Lives 1 Forward-looking Statements This presentation contains certain forward-looking statements about Cytori Therapeutics,
More informationTAKING CARE OF YOUR RHEUMATOID ARTHRITIS
TAKING CARE OF YOUR RHEUMATOID ARTHRITIS RHEUMATOID ARTHRITIS (RA) FAST FACTS What is Rheumatoid Arthritis? Rheumatoid arthritis (RA) is a chronic disease that can affect your ability to function and be
More information